OKYO Pharma to Include Additional Analyses in Upcoming Dry Eye Disease Key Opinion Leader Event | NASDAQ:OKYO

Proactive InvestorsApr 9 16:36

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024.

GlobeNewswireApr 9 07:00

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

London and New York, NY, April 2, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye

OKYO PharmaApr 2 12:00

Borr Drilling, Aehr Test Systems, Airship AI Among Premarket Losers' Pack

Seeking AlphaMar 25 20:41

Relief For Dry Eye Disease? OKYO Pharma's Candidate Shows Durable Pain Relief In Mid-Stage Study

OKYO Pharma Limited (NASDAQ:OKYO) announced additional key findings from analyses of the clinical data set from the 240-patient Phase 2 trial evaluating the safety and efficacy of OK-101 (0.05%) ophth

BenzingaMar 22 23:53

OKYO Pharma Is Maintained at Buy by HC Wainwright & Co.

OKYO Pharma Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMar 22 23:15